TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
Want to see RNAZ full AI Analyst Report?
RNAZ Stock Chart & Stats
$6.96
-$0.12(-3.32%)
At close: 4:00 PM EST
$6.96
-$0.12(-3.32%)
Day’s Range― - ―
52-Week Range$3.82 - $20.99
Previous CloseN/A
Volume52.57K
Average Volume (3M)282.59K
Market Cap
$4.72M
Enterprise Value-$7.75M
Total Cash (Recent Filing)$12.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding950,302
10 Day Avg. Volume825,542
30 Day Avg. Volume282,592
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit183.86
Enterprise Value/Ebitda0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Strategic PartnershipsThe company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.
Bears Say
Financial RisksRisks include, but are not limited to: safety signals emerge with any of the company’s clinical or preclinical programs.
Operating ExpensesIn 4Q24, the company reported operating expenses of $5.1M, which was significantly higher than 3Q24, likely associated with costs related to dose escalation in the Phase 1 trial of TTX-MC138 for treatment of solid tumors.
TransCode Therapeutics News
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $3.82 and its highest was $20.99 in the past 12 months.
What is TransCode Therapeutics’s market cap?
TransCode Therapeutics’s market cap is $4.72M.
When is TransCode Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TransCode Therapeutics’s earnings last quarter?
Currently, no data Available
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Overvalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 950,302 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TransCode Therapeutics
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.48% Mutual Funds
1.23% Other Institutional Investors
96.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---